Xilio Therapeutics, Inc. (XLO)

NASDAQ: XLO · IEX Real-Time Price · USD

0.970

+0.045 (4.90%)

At close: Jul 19, 2024, 4:00 PM

0.930

-0.040 (-4.15%)

Pre-market: Jul 22, 2024, 9:02 AM EDT

Xilio Therapeutics Employees

Xilio Therapeutics had 73 employees as of December 31, 2023. The number of employees decreased by 16 or -17.98% compared to the previous year.

Employees

73

Change (1Y)

-16

Growth (1Y)

-17.98%

Revenue / Employee

n/a

Profits / Employee

-$972,068

Market Cap

35.81M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	73	-16	-17.98%
Dec 31, 2022	89	15	20.27%
Dec 31, 2021	74	-	-

Related Stocks

Company Name	Employees
DarioHealth	294
Aadi Bioscience	89
Precision Optics Corporation	85
IceCure Medical	77
iCAD, Inc.	69
IGC Pharma	67
Aligos Therapeutics	66
Cue Biopharma	53

Employee Rankings

XLO News

5 weeks ago - Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D. - GlobeNewsWire
2 months ago - Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results - GlobeNewsWire
3 months ago - Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
4 months ago - Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing - GlobeNewsWire
4 months ago - Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program - Business Wire
5 months ago - Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference - GlobeNewsWire
6 months ago - Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference - GlobeNewsWire
7 months ago - Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies - GlobeNewsWire